Cover Image
市場調查報告書

PharmaPoint:精神分裂症--全球醫藥品的預測與市場分析

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 300563
出版日期 內容資訊 英文 253 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:精神分裂症--全球醫藥品的預測與市場分析 PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2022
出版日期: 2014年02月28日 內容資訊: 英文 253 Pages
簡介

根據世界衛生組織(WHO)專家推測,全球整體有2400萬名精神分裂症患者。雖然非典型抗精神病藥物的出現,讓這二十年來藥理療法的選擇大幅擴大,但相關的陰性症狀、癡呆症方面則尚未有治療藥上市。長效性注射劑(LAI)日益暢銷、對陰性、癡呆症惡化中的患者有效果的新治療法的出現等,是今後市場的推動要素。此外,配合各國固有的情勢之治療方針及政策推動,更是今後發展精神疾病治療所不可或缺的。

本報告提供全球的精神分裂症治療藥市場現況與未來展望相關分析,提供疾病概要和今後的流行病學的預測,主要國家的治療體制,再加上主要企業簡介與代表性產品,市場未滿足需求與未來性的機會,現在臨床實驗中的開發中產品的資訊,今後的市場規模及影響要素等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理
  • 症狀

第4章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
    • 精神疾病的家族病史(一等親血緣者):強力的預測因素
    • 父親的年齡高的情況,兒童的發病風險也高
    • 經常會併發其他的精神疾病
    • 許多患者甚至會併發複數的併發症
  • 全球各國的趨勢
    • 美國
    • 歐洲主要5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 精神分裂症的流行病學的預測(今後11年份)
    • 受診斷的患病人數
    • 各年齡的患病人數
    • 男女的患病人數
    • 年齡已調整的患病人數
  • 議論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷
    • 主觀的評估
    • 疾病的分類
  • 治療概要
    • 精神分裂症相關急性激越的治療方法
    • 精神分裂症的維持療法
  • 美國
    • 診斷
    • 臨床診療
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估
  • 產品簡介:世代別
    • 傳統的抗精神病藥
    • 非典型抗精神病藥物

第7章 市場機會及未滿足需求

  • 未滿足需求
    • 一般的認知度
    • 早期診斷·治療
    • 長效型·最尖端的藥物遞輸系統
    • 陰性症狀·癡呆症狀有效的管理
  • 差距分析
    • 長效型的藥物遞輸
    • 陰性症狀·癡呆症狀的治療

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖(定位)
    • 各國臨床實驗製圖(定位)
    • Phase別·各階段臨床實驗進展
  • 初期階段產品開發中產品的評估
  • 新的治療方法
    • 陰性症狀
    • 癡呆症狀
  • 長效型的藥物遞輸
  • 技術趨勢分析
  • 臨床實驗階段的主要醫藥品
    • Aripiprazole Lauroxil
    • Cariprazine
    • Brexpiprazole
    • Zicronapine
    • Bitopertin
    • EVP-6124

第9章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Janssen Pharmaceuticals
    • Eli Lilly and Company
    • Roche
    • Alkermes
    • EnVivo Pharmaceuticals

第10章 市場預測

  • 全球市場
    • 未來預測
    • 市場促進·阻礙因素
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第11章 附錄

圖表一覽

目錄
Product Code: GDHC81PIDR

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Highlights

Key Questions Answered

  • What are the preferred antipsychotic therapies for each country?
  • The developmental pipeline consists of LAI antipsychotics that address medication compliance concerns. Which of these LAIs will attain high sales revenues during 2012-2022 and in which markets?
  • Will LAI antipsychotics face adoption challenges in the market? What is the projected uptake of new LAIs, such as Otsuka/Lundbeck's Abilify Maintena and Alkermes' Aripiprazole lauroxil, over the forecast period?
  • How large an impact will bitopertin and EVP-6124 have on the schizophrenia market? What do key opinion leaders think of these treatment approaches?
  • What governmental and industry developments are likely to affect healthcare access and treatment rates in the markets researched? Which is the largest growth market globally?

Key Findings

  • Country-specific mental health policy heavily influences antipsychotics prescribing patterns and sales in the marketplace.
  • The impact of negative and cognitive symptom therapies in the marketplace will be challenging without the use of biomarkers and laboratory measurements that can demonstrate a patient's response to treatment.
  • Patient and prescriber endorsements of new and existing LAIs, in particular, atypical LAI antipsychotics, are anticipated to dramatically influence market growth.
  • Major players will leverage their R&D, manufacturing, and distribution networks to maintain their stakes in the market.

Scope

  • Overview of schizophrenia, including etiology, general symptoms, and country-specific treatment recommendations and compliance data.
  • Annualized schizophrenia market revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the schizophrenia market.
  • Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically as Otsuka/Lundbeck's Abilify Maintena and Alkermes' Aripiprazole lauroxil.
  • Analysis of the current and future market competition in the global schizophrenia drug market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the schizophrenia market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global schizophrenia market from 2012-2022.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. Psychiatric illness in first-degree relatives is. strong predictor of schizophrenia
    • 4.2.2. Advancing paternal age increases the risk of schizophrenia in offspring
    • 4.2.3. Psychiatric comorbidities are common in patients with schizophrenia
    • 4.2.4. People with schizophrenia suffer from several medical comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods, Prevalent Cases
  • 4.5. Epidemiological Forecast of Schizophrenia (2012-2022)
    • 4.5.1. Diagnosed Prevalent Cases of Schizophrenia
    • 4.5.2. Age-Specific Prevalent Cases of Schizophrenia
    • 4.5.3. Sex-Specific Prevalent Cases of Schizophrenia
    • 4.5.4. Age-Standardized Diagnosed Prevalence of Schizophrenia
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis
    • 5.1.1. Subjective Assessments
    • 5.1.2. Disease Subtypes
  • 5.2. Treatment Overview
    • 5.2.1. Treatment of Acute Agitation Associated with Schizophrenia
    • 5.2.2. Maintenance Treatment of Schizophrenia
  • 5.3. US
    • 5.3.1. Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. France
    • 5.4.1. Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Germany
    • 5.5.1. Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Italy
    • 5.6.1. Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. Spain
    • 5.7.1. Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. UK
    • 5.8.1. Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. Japan
    • 5.9.1. Diagnosis
    • 5.9.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles by Generation
    • 6.3.1. Conventional Antipsychotics
    • 6.3.2. Atypical Antipsychotics

7. Opportunity and Unmet Need

  • 7.1. Unmet Needs Overview
    • 7.1.1. Public Awareness
    • 7.1.2. Early Diagnosis and Treatment
    • 7.1.3. Long-Acting and Advanced Drug Delivery Systems
    • 7.1.4. Effective Management of Negative and Cognitive Symptom Domains
  • 7.2. Gap Analysis
    • 7.2.1. Long-Acting Drug Delivery
    • 7.2.2. Treatment of Negative and Cognitive Symptoms

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
    • 8.2.2. Clinical Trials by Phase and Trial Status
  • 8.3. Early-Stage Pipeline Assessment
  • 8.4. Novel Therapeutic Approaches
    • 8.4.1. Negative Symptoms
    • 8.4.2. Cognitive Symptoms
  • 8.5. Long-Acting Drug Delivery
  • 8.6. Technology Trends Analysis
  • 8.7. Key Drugs in Clinical Development
    • 8.7.1. Aripiprazole Lauroxil
    • 8.7.2. Cariprazine
    • 8.7.3. Brexpiprazole
    • 8.7.4. Zicronapine
    • 8.7.5. Bitopertin
    • 8.7.6. EVP-6124

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Janssen Pharmaceuticals
    • 9.3.2. Eli Lilly and Company
    • 9.3.3. Roche
    • 9.3.4. Alkermes
    • 9.3.5. EnVivo Pharmaceuticals

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Global Drivers and Barriers
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. UK
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosis and Treatment Rates
    • 11.4.2. Adherence Rates
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Key Opinion Leaders
  • 11.6. About the Authors
    • 11.6.1. Author
    • 11.6.2. Epidemiology
    • 11.6.3. Reviewers
    • 11.6.4. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Symptom Clusters of Schizophrenia
  • Table 2: ICD-9 Codes and Classification of Schizophrenia
  • Table 3: Risk Factors and Comorbidities for Schizophrenia
  • Table 4: Prevalence of Most Frequent Comorbidities in People with Schizophrenia and People without Schizophrenia, Both Sexes, Ages ≥18 Years, 2007
  • Table 5: Prevalence of Most Frequent Comorbidities in People with Schizophrenia and People without Schizophrenia, 1996-2001
  • Table 6: Distribution of Estimates of Schizophrenia from Three Meta-Analysis Studies of Incidence, Prevalence, and Mortality, by Sex
  • Table 7: Trends in the Annual Incidence of Schizophrenia (per 100,000 Population), Portogruaro, Italy, 1982-1989
  • Table 8: Trends in the Prevalence of Schizophrenia (per 1,000 Population), Portogruaro, Italy, 1982-1989
  • Table 9: Trends in the Prevalence of Schizophrenia (per 1,000 Population), Japan, 1984-2008
  • Table 10: Sources of Schizophrenia Prevalence Data
  • Table 11: 7MM, Diagnosed Prevalent Cases of Schizophrenia, Both Sexes, Ages ≥15 Years, N, 2012-2022
  • Table 12: 7MM, Age-Specific Diagnosed Prevalent Cases of Schizophrenia, Both Sexes, N (Row %), 2012
  • Table 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of Schizophrenia, Ages ≥15 Years, N (Row %), 2012
  • Table 14: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis
  • Table 15: Development-Based Classification of Antipsychotic Drugs
  • Table 16: Receptor Binding Profiles of Atypical Antipsychotics
  • Table 17: Guidelines for the Treatment of Schizophrenia
  • Table 18: Leading Branded Treatments for Schizophrenia, 2013
  • Table 19: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014
  • Table 20: Chemical Classifications of FGAs
  • Table 21: Receptor Affinity Profiles for FGAs
  • Table 22: First-Generation Antipsychotics SWOT Analysis, 2013
  • Table 23: Global Sales Forecast ($m) for First-Generation Antipsychotics, 2012-2022
  • Table 24: Product Profile - Abilify
  • Table 25: Abilify SWOT Analysis, 2014
  • Table 26: Global Sales Forecast ($m) for Abilify, 2012-2022
  • Table 27: Product Profile - Saphris
  • Table 28: Saphris SWOT Analysis, 2013
  • Table 29: Global Sales Forecast ($m) for Saphris, 2012-2022
  • Table 30: Product Profile - Clozaril
  • Table 31: Clozaril SWOT Analysis, 2014
  • Table 32: Global Sales Forecast ($m) for Clozaril, 2012-2022
  • Table 33: Product Profile - Fanapt
  • Table 34: Fanapt SWOT Analysis, 2014
  • Table 35: Global Sales Forecast ($m) for Fanapt, 2012-2022
  • Table 36: Product Profile - Latuda
  • Table 37: Latuda SWOT Analysis, 2014
  • Table 38: Global Sales Forecasts ($m) for Latuda, 2012-2022
  • Table 39: Product Profile - Zyprexa
  • Table 40: Zyprexa SWOT Analysis, 2014
  • Table 41: Global Sales Forecast ($m) for Zyprexa, 2012-2022
  • Table 42: Product Profile - Invega
  • Table 43: Invega SWOT Analysis, 2013
  • Table 44: Global Sales Forecast ($m) for Invega, 2012-2022
  • Table 45: Product Profile - Seroquel
  • Table 46: Seroquel SWOT Analysis, 2013
  • Table 47: Global Sales Forecast ($m) for Seroquel, 2012-2022
  • Table 48: Product Profile - Risperdal
  • Table 49: Risperdal SWOT Analysis, 2013
  • Table 50: Global Sales Forecast ($m) for Risperdal, 2012-2022
  • Table 51: Product Profile - Geodon
  • Table 52: Geodon SWOT Analysis, 2013
  • Table 53: Global Sales Forecasts ($m) for Geodon, 2012-2022
  • Table 54: Unmet Needs - Current Level of Attainment
  • Table 55: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 56: Schizophrenia - Clinical Trials by Phase and Status, Global, 2014
  • Table 57: Technological Trends Analytic Framework in the Schizophrenia Pipeline, 2014
  • Table 58: Pipeline Candidates in Development for Schizophrenia, 2014
  • Table 59: Comparison of Novel Therapeutic Classes in Development for Schizophrenia, 2013
  • Table 60: Product Profile - Aripiprazole Lauroxil
  • Table 61: Aripiprazole Lauroxil SWOT Analysis, 2014
  • Table 62: Global Sales Forecast ($m) for Aripiprazole Lauroxil, 2012-2022
  • Table 63: Product Profile - Cariprazine
  • Table 64: Cariprazine SWOT Analysis, 2014
  • Table 65: Global Sales Forecast ($m) for Cariprazine, 2012-2022
  • Table 66: Product Profile - Brexpiprazole
  • Table 67: Brexpiprazole SWOT Analysis, 2014
  • Table 68: Global Sales Forecasts ($m) for Brexpiprazole, 2012-2022
  • Table 69: Product Profile - Zicronapine
  • Table 70: Zicronapine SWOT Analysis, 2014
  • Table 71: Global Sales Forecast ($m) for Zicronapine, 2012-2022
  • Table 72: Product Profile - Bitopertin
  • Table 73: Bitopertin SWOT Analysis, 2014
  • Table 74: Global Sales Forecast ($m) for Bitopertin, 2012-2022
  • Table 75: Product Profile - EVP-6124
  • Table 76: EVP-6124 SWOT Analysis, 2014
  • Table 77: Global Sales Forecast ($m) for EVP-6124, 2012-2022
  • Table 78: Janssen Schizophrenia Portfolio Assessment, 2014
  • Table 79: Janssen SWOT Analysis, 2014
  • Table 80: Eli Lilly Schizophrenia Portfolio Assessment, 2014
  • Table 81: Eli Lilly SWOT Analysis, 2014
  • Table 82: Roche Schizophrenia Portfolio Assessment, 2014
  • Table 83: Roche SWOT Analysis, 2014
  • Table 84: Alkermes Schizophrenia Portfolio Assessment, 2014
  • Table 85: Alkermes SWOT Analysis, 2014
  • Table 86: EnVivo Schizophrenia Portfolio Assessment, 2014
  • Table 87: EnVivo Pharmaceuticals SWOT Analysis, 2014
  • Table 88: Global Sales Forecast ($m) for Schizophrenia, 2012-2022
  • Table 89: Global Schizophrenia Market, Drivers and Barriers, 2012-2022
  • Table 90: Sales Forecast ($m) for Schizophrenia in the US, 2012-2022
  • Table 91: Key Events Impacting Sales for Schizophrenia in the US, 2012-2022
  • Table 92: Schizophrenia Market in the US - Drivers and Barriers, 2012-2022
  • Table 93: Sales Forecast ($m) for Schizophrenia in France, 2012-2022
  • Table 94: Key Events Impacting Sales for Schizophrenia in France, 2012-2022
  • Table 95: Schizophrenia Market in France - Drivers and Barriers, 2012-2022
  • Table 96: Sales Forecast ($m) for Schizophrenia in Germany, 2012-2022
  • Table 97: Key Events Impacting Sales for Schizophrenia in Germany, 2012-2022
  • Table 98: Schizophrenia Market in Germany - Drivers and Barriers, 2012-2022
  • Table 99: Sales Forecast ($m) for Schizophrenia in Italy, 2012-2022
  • Table 100: Key Events Impacting Sales for Schizophrenia in Italy, 2012-2022
  • Table 101: Schizophrenia Market in Italy - Drivers and Barriers, 2012-2022
  • Table 102: Sales Forecast ($m) for Schizophrenia in Spain, 2012-2022
  • Table 103: Key Events Impacting Sales for Schizophrenia in Spain, 2012-2022
  • Table 104: Schizophrenia Market in Spain - Drivers and Barriers, 2012-2022
  • Table 105: Sales Forecast ($m) for Schizophrenia in the UK, 2012-2022
  • Table 106: Key Events Impacting Sales for Schizophrenia in the UK, 2012-2022
  • Table 107: Schizophrenia Market in the UK - Drivers and Barriers, 2012-2022
  • Table 108: Sales Forecast ($m) for Schizophrenia in Japan, 2012-2022
  • Table 109: Key Events Impacting Sales for Schizophrenia in Japan, 2012-2022
  • Table 110: Schizophrenia Market in Japan - Drivers and Barriers, 2012-2022
  • Table 111: Key Launch Dates
  • Table 112: Key Patent Expirations

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of Schizophrenia, Both Sexes, Ages ≥15 Years, N, 2012-2022
  • Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of Schizophrenia, Both Sexes, N, 2012
  • Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of Schizophrenia, Ages ≥15 Years, N, 2012
  • Figure 4: 6MM, Age-Standardized Diagnosed Prevalence (%) of Schizophrenia, Ages ≥15 Years, by Sex, 2012
  • Figure 5: Active Schizophrenia Clinical Trials by Location in the 7MM, 2014
  • Figure 6: Schizophrenia - Pipeline Drugs by Target, 2014
  • Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in Schizophrenia, 2012-2022
  • Figure 8: Schizophrenia Therapeutics - Pipeline by Company, 2014
  • Figure 9: Global Schizophrenia Drug Sales by Region, 2012-2022
  • Figure 10: Sales for Schizophrenia in the US by Drug Class, 2012-2022
  • Figure 11: Sales for Schizophrenia in France by Drug Class, 2012-2022
  • Figure 12: Sales for Schizophrenia in Germany by Drug Class, 2012-2022
  • Figure 13: Sales for Schizophrenia in Italy by Drug Class, 2012-2022
  • Figure 14: Sales for Schizophrenia in Spain by Drug Class, 2012-2022
  • Figure 15: Sales for Schizophrenia in the UK by Drug Class, 2012-2022
  • Figure 16: Sales for Schizophrenia in Japan by Drug Class, 2012-2022
Back to Top